Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
AlphaNavi Pharma Inc. logo — AlphaNavi Pharma is developing a unique voltage-gated sodium...

AlphaNavi Pharma Inc.

AlphaNavi Pharma is developing a unique voltage-gated sodium channel inhibitor for neuropathic pain.

Founded 2019 Japan Japan 4 employees Series A Total: $900.00M Biotechnology, Health Care +1

General Information

Company Name AlphaNavi Pharma Inc.
Founded Year 2019
Location Japan Japan
Employees 4
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with AlphaNavi Pharma Inc.. To contact AlphaNavi Pharma Inc., visit alphanavi.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does AlphaNavi Pharma Inc. compare?

A PDF of AlphaNavi Pharma Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting AlphaNavi Pharma Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About AlphaNavi Pharma Inc.

AlphaNavi Pharma Inc. is a biotechnology startup based in Japan, founded in 2019. The company is focused on developing a unique voltage-gated sodium channel inhibitor, ANP-230, for the treatment of neuropathic pain, particularly targeting Nav1.7, Nav1.8, and Nav1.9. This compound is also aimed at addressing rare pain diseases caused by mutations in these channels. Notably, ANP-230 is one of the few clinical-stage compounds that inhibit Nav1.9. With a successful track record in Phase 1 studies conducted in the US, UK, and Japan, ANP-230 has demonstrated promising tolerability and proof-of-mechanism signals in human pain challenge studies. The company has also received significant backing, with a ¥900.00M Series A investment on 05 April 2019 from a consortium of notable investors including Nippon Venture Capital, SMBC Venture Capital, Shinsei Capital Partners, Dainippon Sumitomo Pharma, Chushin Venture Capital, Kyoto University Innovation Capital, and Chuo Shinkin Venture Capital. Currently, AlphaNavi Pharma is actively pursuing a Phase 1/2 study of ANP-230 for treating Nav1.9 mutated familial episodic limb pain in Japan. In addition, the company is exploring opportunities for out-licensing, aiming to expand the clinical development of ANP-230 in key markets such as the US, EU, and China. With its novel approach and strong investor support, AlphaNavi Pharma is well-positioned in the field of pharmaceutical innovation targeted at addressing unmet medical needs associated with neuropathic pain.

Business keywords: pharmaceuticals, neuropathic pain, analgesic drug, sodium channel inhibitor, clinical development, pain management, rare pain diseases, precision medicine, Phase 1/2 study, out-licensing, academic collaboration, investor collaboration

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A ¥900.00M 7
Nippon Venture Capital SMBC Venture Capital Shinsei Capital Partners
Nippon Venture Capital, SMBC Venture Capital +5
05 Apr 2019

AlphaNavi Pharma Inc. Alternatives & Competitors

View All Alternatives
AlphaNavi Pharma Inc. vs
ALGOMEDIX, INC.
ALGOMEDIX, INC. United States

2 employees
Biotechnology, Health and Wellness
AlphaNavi Pharma Inc. vs
Synerkine Pharma
Synerkine Pharma The Netherlands

Creating Innovative Pain Solutions

Series A
6 employees
Biotechnology, Health Care
AlphaNavi Pharma Inc. vs
Semnur Pharmaceuticals, Inc.
Semnur Pharmaceuticals, Inc. United States

Semnur Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the clinical and comme...

Venture round
2 employees
Biotechnology, Pharmaceutical
View all alternatives

FAQ About AlphaNavi Pharma Inc.

AlphaNavi Pharma is developing a unique voltage-gated sodium channel inhibitor for neuropathic pain.
AlphaNavi Pharma Inc. was founded in 2019.
AlphaNavi Pharma Inc. is headquartered in Japan.
AlphaNavi Pharma Inc. operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on pharmaceuticals, neuropathic pain, analgesic drug and sodium channel inhibitor.
AlphaNavi Pharma Inc. has approximately 4 employees.
AlphaNavi Pharma Inc. has completed 1 funding round, raising a total of $900.00M. The latest funding stage is Series A.
Top alternatives and competitors to AlphaNavi Pharma Inc. include ALGOMEDIX, INC., Synerkine Pharma, Semnur Pharmaceuticals, Inc., Cavion, Synlogic. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
AlphaNavi Pharma Inc. and ALGOMEDIX, INC. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for AlphaNavi Pharma Inc., https://bouncewatch.com/company/alphanavi-pharma-inc, updated 19 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout